Healthcare-focused market research firm Trilliant Health published a report detailing the 10 most significant economic trends affecting U.S. healthcare stakeholders in 2023. Some of the main ideas covered in the report included Americans’ worsening physical and mental health, the industry’s shift away from traditional care pathways, and the way patients' decision making is becoming increasingly driven by consumerism.
Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.
7wireVentures launched its largest fund to date on Tuesday the closing of the $217 million digital health fund brings the Chicago-based firm’s assets under management to more than $500 million. Two-thirds of the new fund's capital will be allocated to 7wireVentures’ existing portfolio companies for follow-up investments, and the remaining third will go toward Series B and Series C funding round for companies in which the firm hasn’t yet invested.
Solera Health recently launched HALO, a platform that allows payers and employers to manage both Solera point solution partners and non-Solera point solutions in one place.
It’s critical that we address these examples of institutionalized bias and racism in how we approach clinical trials for drugs and devices. While it’s a daunting task, the path forward is surprisingly clear, and AI can be instrumental in the next step of overcoming unconscious biases inherent in clinical trial processes.